Search

Displaying results 4821 - 4830 of 10000 in total
  1. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

    Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: VOTRIENT® 200 MG, VOTRIENT® 400 MG
  2. Drug

    Panobinostat

    go.drugbank.com/drugs/DB06603
    ApprovedInvestigational

    Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. … Panobinostat is marketed by Novartis under the brand name Farydak.

    Synonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  3. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. … It is currently available under the brand name Removab.

  4. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. … The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.

    Products: Influviran 200 mg/20 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (3 Adet), Influviran 200 mg/20 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (5 Adet)
  5. Drug

    Aplindore

    go.drugbank.com/drugs/DB06620
    Investigational

    Categories: Heterocyclic Compounds, 2-Ring
  6. Drug

    Casopitant

    go.drugbank.com/drugs/DB06634
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring, Neurokinin-1 Receptor Antagonists
  7. Drug

    Arbekacin

    go.drugbank.com/drugs/DB06696
    Investigational

    Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant _Staphylococcus aureus_ (MRSA).

    Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
  8. Drug

    Dexmethylphenidate

    go.drugbank.com/drugs/DB06701
    ApprovedInvestigational

    Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002[A177181]. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193]. … The d-isomer is thought to have greater effect with fewer side effects than the l-isomer or the racemic mixture[A177181].

    Synonyms: methyl (R)-phenyl[(R)-piperidin-2-yl]acetate, D-TMPCategories: Heterocyclic Compounds, 1-Ring
  9. Drug

    Iobenguane

    go.drugbank.com/drugs/DB06704
    ApprovedInvestigational

    Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008.

    Synonyms: 3-iodobenzylguanidine, m-iodobenzylguanidineSalts: Iobenguane I 123, Iobenguane I 131
  10. Drug

    Bendamustine

    go.drugbank.com/drugs/DB06769
    ApprovedInvestigational

    Bendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). … It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: BEN SPAL-P® 25, PURPULZ ® 180 MG/4 ML